SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TYRA

Tyra Biosciences, Inc. (NASDAQ:TYRA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$20.12+$0.39 (+1.98%)
 
Market cap
$1.39B
Insider Score
Analyst consensus
Listed since
Sep 15, 2021
Website
Market Cap$1.39B-9.6%
Revenue (ttm)n/a
Net Incomen/a-52.1%
EPSn/a-41.2%
Shares Out68.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume467,578
Open$19.62
Previous Close$19.73
Day's Range$19.62 - $20.44
52-Week Range$18.25 - $40.65
Beta0.75
AnalystsBuy
Price Target$43.40(+115.71%)
Earnings Daten/a

About TYRA

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Address
2656 State Street, Carlsbad, CA, 92008, US
Market Cap
1.39 billion
Employees
87
Industrial Classification
Biotechnology

Tyra Biosciences, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
8th Percentile Overall Score
TYRA InsiderScore:45 / 99

Tyra Biosciences, Inc. scored higher than 8% of companies evaluated by InsiderBuying, and ranked 84th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Tyra Biosciences, Inc. bought $20.0K of stock across 1 purchase in the last 90 days, the largest of them $20.0K.

Stake Increase

None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$10.59M
Bought
$20.00K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $50.00 (+148.5%)

3 firms rating TYRA in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+1.98%
5 Days
+0.45%
1 Month
-3.59%
6 Months
-38.04%
1 Year
-9.61%

$TYRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TYRA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TYRA's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TYRA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New TYRA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TYRA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TYRA

XBIState Street SPDR S&P Biotech ETF$23.35M
VTIVanguard Morningstar Total Stock Market ETF$20.46M
IWMiShares Russell 2000 ETF$18.94M
VXFVanguard Extended Market ETF$10.54M
IBBiShares Biotechnology ETF$8.11M
IWOiShares Russell 2000 Growth ETF$6.93M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TYRA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
16.74
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
45

News check: Mixed coverage with positive Phase 2 trial data offset by widening Q3 net losses; financial headwinds weigh on early-stage clinical progress.

Recent Insider Activity

Buys
1
Sells
14
Buy Value
$20.00K
Distinct Buyers
1

Insider Score Trend Over Time

+4.6 since Sep 16
0255075100Sep 16 — Insider Score 44.8Sep 17 — Insider Score 43.6Sep 18 — Insider Score 43.0Sep 19 — Insider Score 43.0Sep 20 — Insider Score 43.0Sep 21 — Insider Score 42.5Sep 22 — Insider Score 41.7Sep 23 — Insider Score 40.1Sep 24 — Insider Score 39.4Sep 25 — Insider Score 61.0Sep 26 — Insider Score 60.7Sep 27 — Insider Score 60.8Sep 28 — Insider Score 60.7Sep 29 — Insider Score 60.3Sep 30 — Insider Score 60.0Oct 1 — Insider Score 59.1Oct 2 — Insider Score 44.0Oct 3 — Insider Score 59.9Oct 4 — Insider Score 60.1Oct 5 — Insider Score 58.8Oct 6 — Insider Score 59.2Oct 7 — Insider Score 57.8Oct 8 — Insider Score 57.5Oct 9 — Insider Score 57.4Oct 10 — Insider Score 56.9Oct 11 — Insider Score 58.0Oct 12 — Insider Score 58.0Oct 13 — Insider Score 57.7Oct 14 — Insider Score 57.3Oct 15 — Insider Score 57.3Oct 16 — Insider Score 57.8Oct 17 — Insider Score 57.8Oct 18 — Insider Score 58.1Oct 19 — Insider Score 58.0Oct 20 — Insider Score 57.1Oct 21 — Insider Score 56.9Oct 22 — Insider Score 57.1Oct 23 — Insider Score 56.9Oct 24 — Insider Score 57.0Oct 25 — Insider Score 56.6Oct 26 — Insider Score 56.6Oct 27 — Insider Score 56.7Oct 28 — Insider Score 56.5Oct 29 — Insider Score 56.5Oct 30 — Insider Score 55.3Oct 31 — Insider Score 54.8Nov 1 — Insider Score 55.2Nov 2 — Insider Score 55.2Nov 3 — Insider Score 54.7Nov 4 — Insider Score 54.1Nov 5 — Insider Score 53.6Nov 6 — Insider Score 52.7Nov 7 — Insider Score 52.0Nov 8 — Insider Score 52.9Nov 9 — Insider Score 53.6Nov 10 — Insider Score 52.2Nov 11 — Insider Score 51.3Nov 12 — Insider Score 51.4Nov 13 — Insider Score 50.2Nov 14 — Insider Score 49.4Sep 16Oct 15Nov 14

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SBIOALPS Medical Breakthroughs ETF0.77%
TDNAT. Rowe Price Biotech ETF0.62%
BBCVirtus Biotech Clinical Trials ETF0.57%
CANCTema Oncology ETF0.28%
XBIState Street SPDR S&P Biotech ETF0.23%
PJSMPGIM Jennison Small-Mid Cap Core Equity ETF0.21%
ESSCEventide Small Cap ETF0.15%
OPTZOptimize Strategy Index ETF0.13%
IBBQInvesco Nasdaq Biotechnology ETF0.08%
IBBiShares Biotechnology ETF0.07%
VFMOVanguard U.S. Momentum Factor ETF0.06%
TMSLT. Rowe Price Small-Mid Cap ETF0.05%

Weight is the stock’s share of each fund’s holdings.